Regeneron’s golden goose Eylea may stave off biosimilar competition until 2024 or beyond

Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of about $5 billion per year, or more than half of Regeneron’s annual revenues.